PYXS
What one share of Pyxis Oncology holds
Pharmaceutical Preparations
Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC).
Pyxis Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.40 |
|---|---|
| Cash and investments | $0.52 |
| Book value | $0.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$12.45 | $1.44 | −$11.22 | — | −$12.13 |
| 2021 | — | −$8.95 | $0.06 | −$4.22 | — | — |
| 2022 | — | −$3.65 | $0.19 | −$2.90 | — | $4.60 |
| 2023 | — | −$1.85 | $0.17 | −$1.94 | — | $2.81 |
| 2024 | $0.28 | −$1.32 | $0.00 | −$0.99 | — | $2.01 |
| 2025 | $0.22 | −$1.28 | $0.00 | −$1.02 | — | $0.85 |